Amneal Pharmaceuticals (AMRX) 8-K/A Financial Statements and Exhibits

Exhibit 99.1

AMNEAL PHARMACEUTICALS LLC AND SUBSIDIARIES

FINANCIAL STATEMENTS

AMNEAL PHARMACEUTICALS LLC AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
	(Unaudited; in thousands except unit amounts)
		March 31, 2018		December 31, 2017
	Assets
	Current assets:
	Cash and cash equivalents	$	48,224	$	74,166
	Restricted cash	4,393		3,756
	Trade accounts receivable – net	346,680		351,367
	Inventories	327,886		284,038
	Prepaid expenses and other current assets	37,299		42,396
	Related-party receivables	10,982		16,210
	Total current assets	775,464		771,933
	Property, plant, and equipment – net	489,947		486,758
	Goodwill	26,338		26,444
	Intangible assets – net	48,166		44,599
	Other assets	18,873		12,155
	Total assets	$	1,358,788	$	1,341,889
	Liabilities and members’ deficit
	Current liabilities:
	Accounts payable	$	84,221	$	70,013
	Accrued liabilities	79,887		78,742
	Accrued returns allowance	49,084		45,175
	Current portion of financing obligations	244		311
	Taxes payable	1,076		849
	Revolving credit facility	75,000		75,000
	Current portion of long-term debt	14,171		14,171
	Related-party payables	9,368		12,622
	Total current liabilities	313,051		296,883
	Long-term debt, net	1,352,901		1,355,274
	Long-term portion of financing obligations	39,286		39,987
	Deferred income taxes	2,091		2,491
	Other long-term liabilities	4,726		7,793
	Related party payable – long-term	15,552		15,043
	Total long-term liabilities	$	1,414,556	$	1,420,588
	Members’ equity (189,000,000 units authorized, issued and outstanding at March 31, 2018 and December 31, 2017)	2,716		2,716
	Additional paid-in capital	—		8,562
	Accumulated other comprehensive loss	(24,189)		(14,232)
	Accumulated deficit	(357,980)		(382,785)
	Subtotal – members’ deficit	(379,453)		(385,739)
	Non-controlling interest	10,634		10,157
	Total members’ deficit	(368,819)		(375,582)
	Total liabilities and members’ deficit	$	1,358,788	$	1,341,889

AMNEAL PHARMACEUTICALS LLC AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME
	(Unaudited; in thousands)
		Three months ended
		March 31, 2018		March 31, 2017
	Net revenue	$	275,189	$	225,681
	Cost of goods sold	121,371		104,435
	Depreciation and amortization	9,223		5,230
	Gross profit	144,595		116,016
	Selling, general, and administrative	23,739		26,360
	Research and development	40,063		35,391
	Intellectual property legal development expenses	4,576		6,167
	Depreciation	5,528		5,370
	Acquisition and transaction-related expenses	7,135		—
	Operating profit	63,554		42,728
	Interest expense	(21,051)		(14,161)
	Foreign exchange gain	8,565		14,597
	Other income	948		100
	Total other (expense) income , net	(11,538)		536
	Income before tax	52,016		43,264
	Income tax provision	364		1,003
	Net income	51,652		42,261
	Less net income attributable to non-controlling interest	(117)		(408)
	Net income attributable to Amneal Pharmaceuticals LLC and Subsidiaries	$	51,535	$	41,853

AMNEAL PHARMACEUTICALS LLC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; in thousands)
	Three months ended
	March 31, 2018			March 31, 2017
Operating activities:
Net income	$	51,652		$	42,261
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	14,751			10,600
Unrealized foreign currency gain	(8,327)			(14,245)
Amortization of debt issuance costs	1,170			942
Gain on termination of lease	(3,524)			—
Deferred tax provision	(512)			(577)
Inventory provision	2,845			1,137
Allowance for doubtful accounts provision	93			(120)
Changes in assets and liabilities:
Trade accounts receivable – net	4,981			41,064
Inventories	(47,589)			(18,120)
Prepaid expenses and other current assets	8,185			(45)
Related-party receivables	5,215			4,280
Other assets	(6,694)			(200)
Accounts payable	14,318			(382)
Accrued returns allowance	3,804			2,166
Taxes payable	189			653
Accrued expenses and other current liabilities	(3,846)			1,485
Other liabilities	860			(1,224)
Related-party payables	(10,542)			(267)
Net cash provided by operating activities	$	27,029		$	69,408
Investing activities:
Purchases of property, plant, and equipment	(19,499)			(24,757)
Net cash used in investing activities	$	(19,499	)	$	(24,757	)
Financing activities:
Payments on capital leases	—			(22		)
Repayments on financing obligations	(63		)	(61		)
Net (payments) borrowings from revolving credit line	—			(25,000		)
Payments on term loan debt	(3,543		)	(2,905		)
Equity contributions	—			40
Dividend to non-controlling interest	360			—
Distribution to members	(30,000		)	—
Net cash used in financing activities	$	(33,246	)	$	(27,948	)
Effect of foreign exchange rate on cash	411			1,080
Net (decrease) increase in cash, cash equivalents, and restricted cash	(25,305)			17,783
Cash, cash equivalents, and restricted cash – beginning of period	77,922			37,546
Cash, cash equivalents, and restricted cash – end of period	$	52,617		$	55,329
Cash, and cash equivalents – end of period	48,224			50,297
Restricted cash – end of period	4,393			5,032
Cash, cash equivalents, and restricted cash – end of period	$	52,617		$	55,329
Schedule of Non-Cash Investing and Financing Activities:
Purchases of property, plant, and equipment	1,849			2,083
Additions to intangible assets	5,000			—
Distribution to members	8,562			—